Search Result

Results for "

PKG

" in MedChemExpress (MCE) Product Catalog:

By Targets:	PKG (23) Androgen Receptor (1) Antibiotic (1) Apoptosis (1) Aurora Kinase (1) Autophagy (8) Bacterial (3) Biochemical Assay Reagents (1) Calcium Channel (10) CaMK (1) Endogenous Metabolite (5) HCN Channel (2) HIV (4) Isotope-Labeled Compounds (2) Microtubule/Tubulin (1) Myosin (3) NO Synthase (5) Parasite (2) Phosphodiesterase (PDE) (7) PI4K (1) PKA (14) PKC (10) Potassium Channel (2) ROCK (10)
By Research Areas:	Cancer (15) Cardiovascular Disease (17) Endocrinology (5) Infection (5) Inflammation/Immunology (3) Metabolic Disease (5) Neurological Disease (8)
Click Chemistry:	Alkynes (1)

Inhibitors & Agonists

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Click Chemistry

Targets Recommended: PKG

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P1292

PKG inhibitor peptide	PKG	Cancer
PKG inhibitor peptide is an ATP-competitive inhibitor of cGMP-dependent protein kinase (PKG), with a K_i of 86 μM .

HY-P1561

PKG Substrate	PKG	Neurological Disease
PKG Substrate is a selective substrate for cGMP-dependent protein kinase (PKG).

HY-112197

PKG drug G1 2 Publications Verification	PKG	Cardiovascular Disease
PKG agent G1 targets C42 of PKG Iα. PKG agent G1 can couple to vasodilation and blood pressure lowering by a C42 PKG Iα-independent mechanism.

HY-P2692B

DT-2 acetate 1 Publications Verification	PKG	Cancer
DT-2 is a potent and selective inhibitor of the cGMP-dependent protein kinase (PKG). DT-2 inhibits PKG catalyzed phosphorylation (K_i: 12.5 nM) .

HY-P1292A

PKG inhibitor peptide TFA	PKG	Cancer
PKG inhibitor peptide TFA is an ATP-competitive inhibitor of cGMP-dependent protein kinase (PKG), with a K_i of 86 μM .

HY-151203

PKG1α activator 3	PKG	Cardiovascular Disease
PKG1α activator 3 is a *PKG1α* activator (EC₅₀ basal/partial=13/0.52 μM). PKG1α activator 3 shows anti-proliferative effects to smooth muscle cell, and can be used in cardiovascular disease research .

HY-174130

*PI4Kβ/PKG-IN-1*	Parasite PI4K PKG	Infection
PI4Kβ/PKG-IN-1 (Compound 19) is an orally active dual inhibitor targeting Plasmodium phosphatidylinositol 4-kinase beta (PI4Kβ) and cGMP-dependent protein kinase (PKG). PI4Kβ/PKG-IN-1 exhibits potent antiplasmodial activity. PI4Kβ/PKG-IN-1 is promising for research of malaria .

HY-134332

8-pCPT-5'-AMP 8-(4-Chlorophenylthio)-5'-AMP	PKA PKG	Others
8-pCPT-5'-AMP is an analogue of 5'-AMP and a lipophilic activator of PKA, PKG and Epac (exchange protein activated by cAMP) .

HY-134345

8-pCPT-cGMP-AM 8-(4-Chlorophenylthio)-cGMP-AM	PKG	Neurological Disease
8-pCPT-cGMP-AM (8-(4-Chlorophenylthio)-cGMP-AM) is a highly membrane permeable prodrug of the *PKG* agonist 8-pCPT-cGMP, which increases the membrane permeability of cGMP and is converted to its active form by esterase hydrolysis within the cell, thereby activating *PKG*. 8-pCPT-cGMP-AM can be used to explore the role of cGMP signaling in neural plasticity and memory formation .

HY-134271

8-Br-cGMP-AM	PKG	Cardiovascular Disease
8-Br-cGMP-AM is a derivative of 8-Br-cGMP. As an activator of *PKG* (cGMP-dependent protein kinase), it can lead to a variety of biological effects such as vasodilation and platelet inhibition. 8-Br-cGMP-AM can be used in the study of cardiovascular diseases .

HY-100984

HA-100 1 Publications Verification	PKA PKC Myosin ROCK	Cancer
HA-100 is a potent protein kinase inhibitor, with IC₅₀s of 4 μM, 8 μM, 12 μM and 240 μM for cGMP-dependent protein kinase (PKG), cAMP-dependent protein kinase (PKA), protein kinase C (PKC) and MLC-kinase, respectively. HA-100 also used as a ROCK inhibitor .

HY-100984A

HA-100 hydrochloride	PKA PKC Myosin ROCK	Cancer
HA-100 hydrochloride is a potent protein kinase inhibitor, with IC₅₀s of 4 μM, 8 μM, 12 μM and 240 μM for cGMP-dependent protein kinase (PKG), cAMP-dependent protein kinase (PKA), protein kinase C (PKC) and MLC-kinase, respectively. HA-100 hydrochloride also used as a ROCK inhibitor .

HY-101379A

8-Bromo-cGMP sodium 2 Publications Verification	Calcium Channel	Cardiovascular Disease Neurological Disease
8-Bromo-cGMP sodium, a membrane-permeable analogue of cGMP, is a PKG (protein kinase G) activator. 8-Bromo-cGMP sodium significantly inhibits Ca ²⁺ macroscopic currents and impairs insulin release stimulated with high K ⁺ . 8-Bromo-cGMP sodium has antinociceptive effects and results in vasodilator responses .

HY-137373

Rp-8-pCPT-cGMPS	PKG	Others
Rp-8-pCPT-cGMPS is a competitive inhibitor of cGMP-dependent protein kinase (PKG) (K_i=0.5 μM). Rp-8-pCPT-cGMPS has high lipid solubility and can more easily penetrate the cell membrane and reach sufficient concentration inside the cell to inhibit cGMP-dependent protein kinase. Rp-8-pCPT-cGMPS can be used to study the activity and function of cGMP-dependent protein kinase in platelets .

HY-15720B

Glycyl H-1152 hydrochloride	ROCK Aurora Kinase CaMK	Neurological Disease
Glycyl H-1152 hydrochloride (compound 18) is a glycyl derivative of Rho-kinase inhibitors H-1152 dihydrochloride. Glycyl H-1152 hydrochloride inhibits ROCKII, Aurora A, CAMKII and *PKG, with IC₅₀*s of 0.0118, 2.35, 2.57 and 3.26 μM respectively. Glycyl H-1152 hydrochloride has higher selective than H-1152 hydrochloride .

HY-137665

PET-cGMP	PKG	Cardiovascular Disease
PET-cGMP is a cyclic guanosine monophosphate analog and an effective selective agonist of PKG I, the EC₅₀ of PET-cGMP for PKG Iβ is 3.8 nM, while for PKG II, it's 193 nM .

HY-N6791

KT5823 5+ Cited Publications	PKA PKC Bacterial Apoptosis Antibiotic	Infection Inflammation/Immunology
KT5823, a selective the cGMP-dependent protein kinase (PKG) inhibitor with an K_i value of 0.23 μM, it also inhibits PKA and PKC with K_i values of 10 μM and 4 μM, respectively. KT5823 is a Staurosporine-related protein kinase inhibitor, increases thyroid-stimulating hormone-induced (Na ⁺/I ^- symporter) NIS expression, and iodide uptake in thyroid cells. KT5823 arrests cells after the G0/G1 boundary and causes increases in the levels of apoptotic DNA fragmentation .

HY-137633

Sp-8-Br-PET-cGMPS	PKG	Neurological Disease
Sp-8-Br-PET-cGMPS is a membrane-permeable *PKG* agonist and a membrane-permeable inhibitor of retinal-type cGMP-gated ion channels, as well as an activator of cGMP-dependent protein kinases I α and I β. Sp-8-Br-PET-cGMPS is resistant to mammalian cyclic nucleotide-dependent phosphodiesterases, has no metabolic side effects, and is more lipophilic and permeable than Sp-8-pCPT-cGMPS. Sp-8-Br-PET-cGMPS can be used to study the role of cGMP signaling pathways in the nervous system .

HY-P0142A

DT-3 acetate	PKG	Cardiovascular Disease
DT-3 acetate is a membrane-permeable protein kinase G Iα (PKG Iα) inhibitory peptide and shows pharmacological blockade of the cGMP-PKG signalling .

HY-P0142

DT-3	PKG	Cardiovascular Disease
DT-3 is a membrane-permeable protein kinase G Iα (PKG Iα) inhibitory peptide and shows pharmacological blockade of the cGMP-PKG signalling .

HY-137629

Sp-8-pCPT-PET-cGMPS	PKG	Cardiovascular Disease
Sp-8-pCPT-PET-cGMPS is an activator for *PKG-I. Sp-8-pCPT-PET-cGMPS can be used for research of NO/NOS/sGC/PKG*-I signaling pathway in cardiac differentiation .

HY-155106

SMA4	PKG	Cardiovascular Disease
SMA4 is a selective *PKG1α* activator with basal EC₅₀ value of 29 μM. SMA4 facilitates phosphorylation of the known PKG1 substrate, vasodilator-stimulated phosphoprotein (VASP), and inhibits human pulmonary arterial smooth muscle cells (hPASMC) proliferation. SMA4 can be used for cardiovascular disease research .

HY-U00004

OSIP-486823 CP248	Microtubule/Tubulin	Cancer
OSIP-486823 is a novel microtubule-interfering agent with distinct biological effects on both protein kinase G (PKG) and microtubules.

HY-137622

Sp-cGMPS	PKG	Cardiovascular Disease
Sp-cGMPS is an activator of cGMP-dependent protein kinases (PKGs). Sp-cGMPS can be used in cardiovascular disease-related research .

HY-15979A

H-89 dihydrochloride Maximum Cited Publications 129 Publications Verification	PKA Autophagy	Others
H-89 dihydrochloride is a potent and selective inhibitor of protein kinase A (PKA) with an IC₅₀ of 48 nM and has weak inhibition on PKG, PKC, Casein Kinase.

HY-48958

Protein kinase G inhibitor-1	Bacterial	Infection
Protein kinase G inhibitor-1 (Compound 270) is a mycobacterial protein kinase G inhibitor, with an IC₅₀ of 0.9 μM. Protein kinase G inhibitor-1 can be used for mycobacterial infection research .

HY-130530

AP-C5	Biochemical Assay Reagents	Metabolic Disease
AP-C5 displays selective inhibition of guanosine 3′,5′-cyclic monophosphate (cGMP)-dependent protein kinase II (cGKII) with a pIC₅₀ of 7.2, which can be used for the research of diarrheal disease . AP-C5 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-47597

Protein kinase G inhibitor-2	Bacterial	Infection
Protein kinase G inhibitor-2 (Compound 266) is a mycobacterial protein kinase G inhibitor, with an IC₅₀ of 3 μM. Protein kinase G inhibitor-2 can be used for mycobacterial infection research .

HY-15979

H-89 Maximum Cited Publications 129 Publications Verification	PKA Autophagy	Neurological Disease
H-89 is a potent and selective inhibitor of cyclic AMP-dependent protein kinase (protein kinase A) with IC₅₀ of 48 nM and has weak inhibition on PKG, PKC, Casein Kinase, and others kinases.

HY-N1469R

Kaurenoic acid (Standard)	Potassium Channel	Neurological Disease Inflammation/Immunology
Kaurenoic acid (Standard) is the analytical standard of Kaurenoic acid. This product is intended for research and analytical applications. Kaurenoic acid is a diterpene from Sphagneticola trilobata, inhibits Inflammatory Pain by the inhibition of cytokine production and activation of the NO–cyclic GMP–PKG–ATP-sensitive potassium channel signaling pathway .

HY-137108

Sp-8-pCPT-cGMPS	PKA PKG	Neurological Disease
Sp-8-pCPT-cGMPS is a potent cyclic guanosine monophosphate-gated channel agonist and a lipophilic activator of protein kinase G (types I α, I β, and II) and protein kinase A type II with excellent cell membrane permeability and phosphodiesterase stability. Sp-8-pCPT-cGMPS can be used to study the role of cGMP in neural plasticity and synaptic transmission .

HY-170431

SAL-0010042	Phosphodiesterase (PDE) Parasite	Infection
SAL-0010042 is the inhibitor for Plasmodium phosphodiesterase β (PDEβ), that inhibits the hydrolysis of cAMP and cGMP (IC₅₀=48.9 nM) in gametocytes, activates *PKG, and inhibits the growth and development of Plasmodium* (IC₅₀ for 3D7 and Dd2 is 142 nM and 218 nM). SAL-0010042 inhibits hPDE5 and hPDE6 with IC₅₀ of 632 nM and 73 nM .

HY-12880

HA-100 dihydrochloride	Myosin PKA PKC ROCK	Cancer
HA-100 dihydrochloride is a potent protein kinase inhibitor, with IC₅₀s of 4 μM, 8 μM, 12 μM and 240 μM for cGMP-dependent protein kinase (PKG), cAMP-dependent protein kinase (PKA), protein kinase C (PKC) and MLC-kinase, respectively. HA-100 dihydrochloride also used as a ROCK inhibitor .

HY-130354

Dibutyryl-cGMP sodium 2 Publications Verification Bt2cGMP sodium	Potassium Channel	Cardiovascular Disease
Dibutyryl-cGMP sodium (Bt2cGMP sodium) is a cell-permeable cGMP analogue. Dibutyryl-cGMP sodium preferentially activates cGMP-dependent protein kinase (PKG). Dibutyryl-cGMP sodium inhibits the release of [ ³H]-arachidonic acid from γ thrombin-stimulated human platelets. Dibutyryl-cGMP sodium induces peripheral antinociception via activation of ATP-sensitive K ⁺ channels .

HY-P1556

Vasonatrin Peptide (VNP)	PKG	Cardiovascular Disease
Vasonatrin Peptide (VNP) is a chimera of atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP). Vasonatrin peptide possesses the venodilating actions of CNP, the natriuretic actions of ANP, and unique arterial vasodilating actions not associated with either ANP or CNP. Vasonatrin Peptide protects the diabetic heart against ischemia-reperfusion injury by inhibiting ER stress via the cGMP-PKG signaling pathway .

HY-10341

Fasudil Hydrochloride 15+ Cited Publications HA-1077 Hydrochloride; AT-877 Hydrochloride	ROCK Calcium Channel Autophagy PKA PKC HIV	Cancer
Fasudil (HA-1077; AT877) Hydrochloride is a nonspecific RhoA/ROCK inhibitor and also has inhibitory effect on protein kinases, with an K_i of 0.33 μM for ROCK1, IC₅₀s of 0.158 μM and 4.58 μM, 12.30 μM, 1.650 μM for ROCK2 and PKA, PKC, *PKG*, respectively. Fasudil Hydrochloride is also a potent Ca ²⁺ channel antagonist and vasodilator .

HY-10341C

Fasudil dihydrochloride HA-1077 dihydrochloride; AT-877 dihydrochloride	Calcium Channel ROCK PKA PKC Autophagy HIV	Cancer
Fasudil (HA-1077; AT877) dihydrochloride is a nonspecific RhoA/ROCK inhibitor and also has inhibitory effect on protein kinases, with an K_i of 0.33 μM for ROCK1, IC₅₀s of 0.158 μM and 4.58 μM, 12.30 μM, 1.650 μM for ROCK2 and PKA, PKC, *PKG*, respectively. Fasudil dihydrochloride is also a potent Ca ²⁺ channel antagonist and vasodilator .

HY-10341A

Fasudil HA-1077; AT877	ROCK Calcium Channel Autophagy PKA PKC	Cancer
Fasudil (HA-1077; AT877) is a nonspecific RhoA/ROCK inhibitor and also has inhibitory effect on protein kinases, with an K_i of 0.33 μM for ROCK1, IC₅₀s of 0.158 μM and 4.58 μM, 12.30 μM, 1.650 μM for ROCK2 and PKA, PKC, *PKG*, respectively. Fasudil is also a potent Ca ²⁺ channel antagonist and vasodilator .

HY-P1556A

Vasonatrin Peptide (VNP) TFA	PKG	Metabolic Disease
Vasonatrin Peptide (VNP) TFA is a chimera of atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP). Vasonatrin peptide TFA possesses the venodilating actions of CNP, the natriuretic actions of ANP, and unique arterial vasodilating actions not associated with either ANP or CNP. Vasonatrin Peptide TFA protects the diabetic heart against ischemia-reperfusion injury by inhibiting ER stress via the cGMP-PKG signaling pathway .

HY-10341B

Fasudil hydrochloride semihydrate HA-1077 hydrochloride semihydrate; AT877 hydrochloride semihydrate	ROCK Calcium Channel Autophagy HIV PKA PKC	Cancer
Fasudil (HA-1077; AT877) hydrochloride semihydrate is a nonspecific RhoA/ROCK inhibitor and also has inhibitory effect on protein kinases, with an K_i of 0.33 μM for ROCK1, IC₅₀s of 0.158 μM and 4.58 μM, 12.30 μM, 1.650 μM for ROCK2 and PKA, PKC, *PKG*, respectively. Fasudil hydrochloride semihydrate is also a potent Ca ²⁺ channel antagonist and vasodilator .

HY-10341D

Fasudil mesylate HA-1077 mesylate; AT-877 mesylate	ROCK Calcium Channel Autophagy PKA PKC	Cancer
Fasudil (HA-1077; AT877) mesylate is a nonspecific and orally active RhoA/ROCK inhibitor and also has inhibitory effect on protein kinases, with an K_i of 0.33 μM for ROCK1, IC₅₀s of 0.158 μM and 4.58 μM, 12.30 μM, 1.650 μM for ROCK2 and PKA, PKC, *PKG*, respectively. Fasudil mesylate is also a potent Ca ²⁺ channel antagonist and vasodilator .

HY-135110

Rp-8-Br-cGMPS sodium Rp-8-bromo-Cyclic GMPS sodium	Calcium Channel PKG HCN Channel	Metabolic Disease
Rp-8-Br-cGMPS (Rp-8-bromo-Cyclic GMPS) sodium salt is a potent Ca ²⁺-ATPase activator. Rp-8-Br-cGMPS is also an agonist of the rod CNG channel and an inhibitor of *PKG*. Rp-8-Br-cGMPS sodium salt mediates cytosolic Ca ²⁺ reduction by activating Ca ²⁺-ATPase and subsequently removing Ca ²⁺ from the cell .

HY-135110A

Rp-8-Br-cGMPS Rp-8-bromo-Cyclic GMPS	Calcium Channel PKG HCN Channel	Metabolic Disease
Rp-8-Br-cGMPS (Rp-8-bromo-Cyclic GMPS) sodium salt is a potent Ca ²⁺-ATPase activator. Rp-8-Br-cGMPS is also an agonist of the rod CNG channel and an inhibitor of *PKG*. Rp-8-Br-cGMPS sodium salt mediates cytosolic Ca ²⁺ reduction by activating Ca ²⁺-ATPase and subsequently removing Ca ²⁺ from the cell .

HY-173640

ID11916	Androgen Receptor Phosphodiesterase (PDE)	Cancer
ID11916 is an orally active androgen receptor (AR) antagonist and a phosphodiesterase 5 (PDE5) inhibitor. ID11916 blocks androgen binding to AR, nuclear translocation, and androgen-dependent transcriptional activity of AR, while increasing intracellular cGMP levels and activating PKG via inhibition. ID11916 shows potent anti-cancer effect in prostate cancer cell lines VCaP and 22Rv1 and in AR-positive breast cancer cell lines SK-BR-3 .

HY-10341R

Fasudil (Hydrochloride) (Standard)	ROCK Calcium Channel Autophagy PKA PKC HIV	Cancer
Fasudil (Hydrochloride) (Standard) is the analytical standard of Fasudil (Hydrochloride). This product is intended for research and analytical applications. Fasudil (HA-1077; AT877) Hydrochloride is a nonspecific RhoA/ROCK inhibitor and also has inhibitory effect on protein kinases, with an K_i of 0.33 μM for ROCK1, IC₅₀s of 0.158 μM and 4.58 μM, 12.30 μM, 1.650 μM for ROCK2 and PKA, PKC, *PKG*, respectively. Fasudil Hydrochloride is also a potent Ca ²⁺ channel antagonist and vasodilator .

HY-18252

Avanafil 1 Publications Verification TA1790	Phosphodiesterase (PDE) NO Synthase Endogenous Metabolite	Cardiovascular Disease Endocrinology
Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC₅₀ values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .

HY-18252R

Avanafil (Standard)	Phosphodiesterase (PDE) NO Synthase Endogenous Metabolite	Cardiovascular Disease Endocrinology
Avanafil (Standard) is the analytical standard of Avanafil. This product is intended for research and analytical applications. Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC50 values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .

HY-18252A

Avanafil dibenzenesulfonate TA1790 dibenzenesulfonate	Phosphodiesterase (PDE) NO Synthase Endogenous Metabolite	Cardiovascular Disease Endocrinology
Avanafil (TA-1790) dibenzenesulfonate is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC₅₀ values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil dibenzenesulfonate activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil dibenzenesulfonate inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil dibenzenesulfonate can be used for the research of erectile dysfunction and osteoporosis .

HY-113972R

Methyl mycophenolate (Standard)	Others	Inflammation/Immunology
Avanafil (Standard) is the analytical standard of Avanafil. This product is intended for research and analytical applications. Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC50 values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .

HY-18252S3

Avanafil-13C5 TA1790-¹³C₅	Isotope-Labeled Compounds Endogenous Metabolite Phosphodiesterase (PDE) NO Synthase	Cardiovascular Disease Endocrinology
Avanafil- ¹³C₅ (TA1790- ¹³C₅) is ¹³C labeled Avanafil. Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC₅₀ values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .

Cat. No.	Product Name	Target	Research Area

HY-P1292

PKG inhibitor peptide	PKG	Cancer
PKG inhibitor peptide is an ATP-competitive inhibitor of cGMP-dependent protein kinase (PKG), with a K_i of 86 μM .

HY-P1561

PKG Substrate	PKG	Neurological Disease
PKG Substrate is a selective substrate for cGMP-dependent protein kinase (PKG).

HY-P2692B

DT-2 acetate 1 Publications Verification	PKG	Cancer
DT-2 is a potent and selective inhibitor of the cGMP-dependent protein kinase (PKG). DT-2 inhibits PKG catalyzed phosphorylation (K_i: 12.5 nM) .

HY-P0142A

DT-3 acetate	PKG	Cardiovascular Disease
DT-3 acetate is a membrane-permeable protein kinase G Iα (PKG Iα) inhibitory peptide and shows pharmacological blockade of the cGMP-PKG signalling .

HY-P1556A

Vasonatrin Peptide (VNP) TFA	PKG	Metabolic Disease
Vasonatrin Peptide (VNP) TFA is a chimera of atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP). Vasonatrin peptide TFA possesses the venodilating actions of CNP, the natriuretic actions of ANP, and unique arterial vasodilating actions not associated with either ANP or CNP. Vasonatrin Peptide TFA protects the diabetic heart against ischemia-reperfusion injury by inhibiting ER stress via the cGMP-PKG signaling pathway .

HY-P1292A

PKG inhibitor peptide TFA	PKG	Cancer
PKG inhibitor peptide TFA is an ATP-competitive inhibitor of cGMP-dependent protein kinase (PKG), with a K_i of 86 μM .

HY-P2692A

DT-2	Peptides	Cancer
DT-2 is a potent and selective inhibitor of the cGMP-dependent protein kinase (PKG). DT-2 inhibits PKG catalyzed phosphorylation (K_{i_{: 12.5 nM) .}}

HY-P0142

DT-3	PKG	Cardiovascular Disease
DT-3 is a membrane-permeable protein kinase G Iα (PKG Iα) inhibitory peptide and shows pharmacological blockade of the cGMP-PKG signalling .

HY-P1556

Vasonatrin Peptide (VNP)	PKG	Cardiovascular Disease
Vasonatrin Peptide (VNP) is a chimera of atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP). Vasonatrin peptide possesses the venodilating actions of CNP, the natriuretic actions of ANP, and unique arterial vasodilating actions not associated with either ANP or CNP. Vasonatrin Peptide protects the diabetic heart against ischemia-reperfusion injury by inhibiting ER stress via the cGMP-PKG signaling pathway .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-18252

Avanafil 1 Publications Verification TA1790	Cardiovascular Disease Structural Classification Natural Products Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields Endocrinology	Phosphodiesterase (PDE) NO Synthase Endogenous Metabolite
Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC₅₀ values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .

HY-N1469R

Kaurenoic acid (Standard)	Structural Classification other families Terpenoids Source classification Diterpenoids Senna siamea (Lamarck) H. S. Irwin & Barneby Plants Compositae	Potassium Channel
Kaurenoic acid (Standard) is the analytical standard of Kaurenoic acid. This product is intended for research and analytical applications. Kaurenoic acid is a diterpene from Sphagneticola trilobata, inhibits Inflammatory Pain by the inhibition of cytokine production and activation of the NO–cyclic GMP–PKG–ATP-sensitive potassium channel signaling pathway .

HY-18252R

Avanafil (Standard)	Structural Classification Natural Products Source classification Endogenous metabolite	Phosphodiesterase (PDE) NO Synthase Endogenous Metabolite
Avanafil (Standard) is the analytical standard of Avanafil. This product is intended for research and analytical applications. Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC50 values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .

HY-18252A

Avanafil dibenzenesulfonate TA1790 dibenzenesulfonate	Cardiovascular Disease Structural Classification Natural Products Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields Endocrinology	Phosphodiesterase (PDE) NO Synthase Endogenous Metabolite
Avanafil (TA-1790) dibenzenesulfonate is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC₅₀ values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil dibenzenesulfonate activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil dibenzenesulfonate inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil dibenzenesulfonate can be used for the research of erectile dysfunction and osteoporosis .

HY-113972R

Methyl mycophenolate (Standard)	Structural Classification Monophenols Microorganisms Marine natural products Phenols Marine microorganism	Others
Avanafil (Standard) is the analytical standard of Avanafil. This product is intended for research and analytical applications. Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC50 values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .

Cat. No.	Compare	Product Name	Species	Source

HY-P702647

	PRKG1 Protein, Human (sf9, GST) PRKG1; protein kinase cGMP-dependent 1; PKG; cGK; AAT8; PKG1; cGK1; cGKI; cGK 1; PRKG1B; PRKGR1B; cGKI-BETA; cGKI-alpha	Human	Sf9 insect cells
	PRKG1 is a serine/threonine protein kinase that mediates the NO/c signaling pathway and phosphorylates various cellular proteins. It affects platelet activation, smooth muscle contraction, cardiac function, central nervous system processes, etc. PRKG1 Protein, Human (sf9, GST) is the recombinant human-derived PRKG1, expressed by Sf9 insect cells , with GST labeled tag. ,

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-18252S3

Avanafil-13C5

Avanafil- ¹³C₅ (TA1790- ¹³C₅) is ¹³C labeled Avanafil. Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC₅₀ values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .

HY-18252S1

Avanafil-13C5,15N,d2

Avanafil- ¹³C₅, ¹⁵N,d₂ is ¹⁵N and deuterated labeled Avanafil (HY-18252). Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC₅₀ values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .

Cat. No.	Product Name		Classification

HY-130530

AP-C5		Alkynes
AP-C5 displays selective inhibition of guanosine 3′,5′-cyclic monophosphate (cGMP)-dependent protein kinase II (cGKII) with a pIC₅₀ of 7.2, which can be used for the research of diarrheal disease . AP-C5 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks